Barrier antifungal therapy flunks Phase III trial

Barrier Therapeutics antifungal drug Hyphanox failed to demonstrate that it was at least as effective as Pfizer's Diflucan for treating yeast infections in a Phase III trial. "The outcome of the study is disappointing. While we were able to demonstrate that clinical efficacy was not inferior to that of fluconazole, the therapeutic cure, which also includes the mycological assessment, did not meet the non-inferiority criteria," said Dr. Geert Cauwenbergh, chairman and CEO of Princeton, New Jersey-based Barrier. "We will continue to analyze the massive amount of data to determine next steps for this indication."

- read this press release for more

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.